Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update
March 12, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Interim Analysis for Phase 3 HONOR study of Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) inMilitary-Related PTSD Expected in Third Quarter of 2018; Topline Results Expected in Fourth Quarter of...
Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference
March 06, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on discovering and developing...
Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors
February 15, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) today announced the appointment of David L. Grange, a retired U.S. Army Brigadier General, to...
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
February 07, 2018 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical...
Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
January 24, 2018 16:30 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), announced today that it will present at Noble Capital Markets’ Fourteenth Annual Investor...
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
January 23, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of...
Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture)
January 19, 2018 14:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer
January 09, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco
January 03, 2018 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company developing innovative pharmaceutical and biological products to address major public...
Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
December 12, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical and biological products to address...